Advertisement

HIV-Associated Pulmonary Hypertension

  • G. Barbaro

Abstract

About 14 years ago, Kim and Factor reported the first case of HIV-associated pulmonary hypertension [1]. Since then more than 131 cases have been described in the literature [2]. For this reason, HIV-associated pulmonary hypertension has been included as a definite cause of precapillary pulmonary hypertension according to the executive summary of the World Health Organization (WHO) [3]. The incidence of HIV-associated pulmonary hypertension is 1 in 200, much higher than the 1 in 200,000 found in the general population [3]. No differences have been found in the clinical, histologic, and hemodynamic features between patients with HIV-associated pulmonary hypertension and HIV-uninfected patients affected by primary pulmonary hypertension.

Keywords

Pulmonary Hypertension Human Leukocyte Antigen Pulmonary Arterial Hypertension Primary Pulmonary Hypertension Right Atrial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kim KK, Factor SM (1987) Membrano-proliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 18:1293–1296CrossRefPubMedGoogle Scholar
  2. 2.
    Mehta NJ, Khan IA, Mehta RN et al (2000) HIVrelated pulmonary hypertension: analytic review of 131 cases. Chest 118:1133–1141CrossRefPubMedGoogle Scholar
  3. 3.
    Rich S (2000) Executive summary from the World Symposium on Primary Pulmonary Hypertension. Evian, France, 6-10 September 1998, cosponsored by World Health Organization. http://www.who.int/ncd/cvd/pph.html. Cited 14 April 2000Google Scholar
  4. 4.
    Mette SA, Palevsky HI, Pietra GG et al (1992) Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 145:1196–1200PubMedGoogle Scholar
  5. 5.
    Humbert M, Monti G, Fartouk M et al (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11:554–559PubMedGoogle Scholar
  6. 6.
    Giaid A, Yanagisawa M, Langleben D (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732–1739CrossRefPubMedGoogle Scholar
  7. 7.
    Giaid A (1998) Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 114:208S–212SCrossRefPubMedGoogle Scholar
  8. 8.
    Cacoub P, Dorent R, Nataf P et al (1997) Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33:196–200CrossRefPubMedGoogle Scholar
  9. 9.
    Pellicelli AM, Palmieri F, D’Ambrosio C et al (1998) Role of human immunodeficiency virus in primary pulmonary hypertension: case reports. Angiology 49:1005–1011CrossRefPubMedGoogle Scholar
  10. 10.
    Salvi SS (1999) Alfa1-adrenergic hypothesis for pulmonary hypertension. Chest 115:1708–1719CrossRefPubMedGoogle Scholar
  11. 11.
    Tomashefski JF, Hirsch CS (1980) The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol 11:133–145CrossRefPubMedGoogle Scholar
  12. 12.
    Pellicelli AM, Barbaro G, Palmieri F et al (2001) Primary pulmonary hypertension in HIV patients: a systematic review. Angiology 52:31–41PubMedGoogle Scholar
  13. 13.
    Branch CA, Knuepfer MM (1992) Adrenergic mechanisms underlying cardiac and vascular responses to cocaine in conscious rats. J Pharmacol Exp Ther 263:742–751PubMedGoogle Scholar
  14. 14.
    Hadengue A, Benhayoun MK, Lebrec D et al (1991) Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 100:520–528PubMedGoogle Scholar
  15. 15.
    Kuddus RH, Nalesnik MA, Subbotin VM et al (2000) Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes: an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J Hepatol 33:725–732CrossRefPubMedGoogle Scholar
  16. 16.
    Morse JH, Barst RJ, Itescu S et al (1996) Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 153:1299–1301PubMedGoogle Scholar
  17. 17.
    Itescu S, Dalton J, Zhang HZ, Winchester R (1993) Tissue infiltration in a CD8 lymphocytosis syndrome associated with human immunodeficiency virus-1 infection has the phenotypic appearance of an antigenically driven response. J Clin Invest 91:2216–2225CrossRefPubMedGoogle Scholar
  18. 18.
    Itescu S, Brancato LJ, Winchester W (1989) A sicca syndrome in HIV infection: association with HLA-DR5 and CD8 lymphocytosis. Lancet 2:466–468CrossRefPubMedGoogle Scholar
  19. 19.
    McGoon M, Gutterman D, Steen V et al (2004) Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP EvidenceBased Clinical Practice Guidelines. Chest 126:14S–34SCrossRefPubMedGoogle Scholar
  20. 20.
    Barbaro G (2004). Reviewing the clinical aspects of HIV-associated pulmonary hypertension. J Respir Dis 25:289–293Google Scholar
  21. 21.
    Pellicelli A, Palmieri F, Cicalini S et al (2001) Pathogenesis of HIV-related pulmonary hypertension. Ann NY Acad Sci 946:82–94PubMedGoogle Scholar
  22. 22.
    Opravil M, Pechère M, Speich R et al (1997) HIV-associated primary pulmonary hypertension. Am J Respir Crit Care Med 155:990–995PubMedGoogle Scholar
  23. 23.
    Zuber JP, Calmy A, Evison JM et al (2004) Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 38:1178–1185CrossRefPubMedGoogle Scholar
  24. 24.
    Barbaro G, Lucchini A, Pellicelli AM et al (2006) Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 92:1164–1166CrossRefPubMedGoogle Scholar
  25. 25.
    Petiprez P, Brenot F, Azarian R et al (1994) Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 89:2722–2727Google Scholar
  26. 26.
    Aguilar RV, Farber HW (2000) Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 162:1846–1850PubMedGoogle Scholar
  27. 27.
    Sitbon O, Gressin V, Speich R et al (2004) Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170:1212–1217CrossRefPubMedGoogle Scholar
  28. 28.
    Petrosillo N, Pellicelli AM, Boumis F et al (2001) Clinical manifestations of HIV-related pulmonary hypertension. Ann NY Acad Sci 946:223–235PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • G. Barbaro
    • 1
  1. 1.Department of Medical Pathophysiology“Sapienza” University of RomeRomeItaly

Personalised recommendations